Recently, patients suffering from unexpected chronic diseases such as gastric ulcer and reflux esophagitis are increasing due to irregular eating habits, frequent stress, and excessive drinking. Nizatidine is a histamine receptor antagonist that inhibits gastric acid production by locally binding to the histamine H2 receptor and is mainly used as a treatment for gastric ulcer and reflux esophagitis. Lactose can increase drug volume and provide moderate water solubility, but it decreases hardness. To confirm the increase of hardness and stability of drug when lactose is blended with microcrystalline cellulose to make solid dispersion, nizatidine, lactose and microcrystalline cellulose solid dispersion was manufactured by rotary evaporator in methanol/dichloromethane cosolvent condition. For characterization of the solid dispersion, SEM, DSC, XRD and FTIR were performed, and then drug release was confirmed through an in vitro dissolution test. A relatively good inclusion rate was confirmed in a solid dispersion having a ratio of lactose and microcrystalline cellulose of 3:7, and an ideal behavior of immediate release tablet was confirmed by this. As the result of this, it can be confirmed that nizatidine and lactose/microcrystalline cellulose can be used as immediate release tablet for reflux esophagitis.